The role of descending fibers from the rostral ventromedial medulla in opioid analgesia in rats.
There has been controversy as to whether the contribution of descending fibers from the rostral ventromedial medulla to opioid analgesia depends on the nature of the noxious stimulus eliciting pain. In the present study, inactivation of descending fibers by microinjection of muscimol (50 ng) in the rostral ventromedial medulla abolished morphine analgesia in the tail immersion and hot plate tests but decreased morphine analgesia by 60% in the formalin test. Analysis of the dose-response relation for morphine after inactivation of descending fibers revealed that, except for the tail immersion test, high doses of morphine could not overcome the block induced by muscimol. Also, morphine analgesia elicited supraspinally was not detectable when descending fibers were inactivated, suggesting that the analgesic effect of morphine in the brain requires a relay via the rostral ventromedial medulla. The analgesic effect of buprenorphine also depends on the integrity of descending fibers from the rostral ventromedial medulla. The results indicate that descending fibers from the rostral ventromedial medulla are critically important to the analgesic effect of opioids, regardless of the type of noxious stimulation eliciting pain. Residual analgesic effects of opioids after inactivation of descending fibers may be due to peripheral effects in the presence of inflammation.
Gilbert
Annie-Kim
AK
Department of Psychology, McGill University, 1205 Docteur Penfield Avenue, Montreal, Quebec, Canada H3A 1B1. gilberta@mskcc.org
Franklin
Keith B J
KB
D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002047:Buprenorphine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004525:Efferent Pathways / Q000166:cytology / Q000187:drug effects; D005557:Formaldehyde; D018755:GABA Agonists / Q000008:administration & dosage / Q000494:pharmacology; D006358:Hot Temperature / Q000009:adverse effects; D007101:Immersion / Q000009:adverse effects; D007276:Injections, Intraventricular; D008297:Male; D008526:Medulla Oblongata / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D008845:Microinjections; D009118:Muscimol / Q000008:administration & dosage / Q000494:pharmacology; D009412:Nerve Fibers / Q000187:drug effects*; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time / Q000187:drug effects
D000701:Analgesics, Opioid; D018755:GABA Agonists; D005557:Formaldehyde; D009118:Muscimol; D002047:Buprenorphine